First issue, Vol. 1, No. 1 (January–June 2026), will be published in April 2026.
The Article Processing Charge (APC) is waived for submissions until 31 May 2026.
Aims and Scope
Aim of JPTD
The Journal of Pharmacology, Toxicology, and Drug Development (JPTD) aims to provide a high-quality, peer-reviewed international forum for research in pharmacology, toxicology, and drug innovation, fostering the development and dissemination of novel findings in drug discovery, safety evaluation, and therapeutic advancement. It encourages interdisciplinary collaboration among pharmacologists, toxicologists, biomedical scientists, clinicians, and drug developers, supporting rigorous and ethical research that advances understanding of drug actions, toxicity mechanisms, pharmacodynamics, and pharmacokinetics. The journal promotes translational research that bridges basic experimental studies with preclinical and clinical drug development and safety testing, publishing original research articles, review papers, case reports, short communications, and technical reports with methodological integrity and scientific relevance. By facilitating global access to drug research findings and supporting knowledge exchange across institutions and countries, JPTD contributes to improved public health and therapeutic innovation through the dissemination of robust, evidence-based insights into drug safety, efficacy, and development.
Scope of JPTD
JPTD welcomes submissions in (but not restricted to) the following broad subject areas:
1. Drug discovery and development — design, synthesis, and preclinical evaluation of novel therapeutic agents.
2. Pharmacodynamics and pharmacokinetics — dose–response relationships, absorption, distribution, metabolism, excretion (ADME), and bioavailability studies.
3. Toxicology — in vitro and in vivo toxicity assessments, safety pharmacology, toxicokinetics, and toxicity mechanism studies.
4. Pharmacogenomics and personalized medicine — genetic determinants of drug response and individualized therapy strategies.
5. Drug‑drug interactions, combination therapies, and polypharmacy investigations.
6. Preclinical and translational studies — bridging lab research to preclinical models or early‑phase human/clinical research.
7. Novel drug delivery systems and formulation studies connected to pharmacology and safety assessments.
8. Therapeutic innovation for chronic diseases, infectious diseases, neurologic disorders, cancer, metabolic disorders, and emerging health challenges.
9. Biomarker discovery and validation — molecular, genetic, biochemical markers for drug efficacy, toxicity or therapeutic response.
10. Regulatory toxicology, drug safety, risk‑benefit analysis, and ethical aspects of pharmacological research.
11. Natural products, phytopharmacology, herbal medicines, and investigation of traditional remedies in drug discovery and safety studies.
12. Pharmacovigilance, post‑marketing surveillance studies, adverse‑effect reporting, and long-term safety evaluations.
13. Drug repurposing, bioavailability enhancement, pharmacological optimization of existing drugs, and novel therapeutic strategies.
14. Experimental models — cell culture, animal studies, organoids — used for pharmacology and toxicology research.
15. Public health pharmacology, global drug development challenges, access to medicines, and implications of new therapeutic agents on population health.
